American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 3 , Pages 158-163, May 2007

Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals

  • Christos Magopoulos, DDS

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Aristotle University, Thessaloniki, Greece
    • Corresponding Author InformationCorresponding author. Glinou 4-Pilea, 54352 Thessaloniki, Greece. Tel.: +30 2310949711; fax: +30 2310995362.
  • ,
  • Georgios Karakinaris, DDS

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Aristotle University, Thessaloniki, Greece
  • ,
  • Zisis Telioudis, DDS

      Affiliations

    • ‘Theagenio’ Cancer Istitute, Thessaloniki, Greece
  • ,
  • Konstantinos Vahtsevanos, MD, DDS

      Affiliations

    • ‘Theagenio’ Cancer Istitute, Thessaloniki, Greece
  • ,
  • Ioannis Dimitrakopoulos, MD, DDS

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Aristotle University, Thessaloniki, Greece
  • ,
  • Konstantinos Antoniadis, MD, DDS

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Aristotle University, Thessaloniki, Greece
  • ,
  • Sideris Delaroudis, MD

      Affiliations

    • Department of Endocrinology, Military Hospital, Thessaloniki, Greece

Received 15 May 2006

Abstract 

Purpose

Bisphosphonates are compounds used in the treatment of various metabolic and malignant bone diseases. In the last two and a half years, there has been a striking increased referral of patients with exposed necrotic jawbone, mostly after several teeth extractions. The only clinical feature common in all patients was the use of bisphosphonates in the treatment of bone diseases.

Patients and methods

We performed a retrospective multicentric study of 60 patients with necrotic bone lesions of the jaws of various extent from July 2003 to October 2005. The necrotic bone involved the maxilla (37%), the mandible (50%), or both (13%). The bisphosphonate administered was mostly zoledronate. The management of the patients included cessation of bisphosphonate therapy for more than 6 months, long-term antibiotics, hyperbaric oxygen administration in some cases, and various surgical restorative procedures.

Results

The implementation of the treatment protocol in 7 patients so far lead to high cure rates, whereas surgical restoration of the defect without previous cessation of bisphosphonate therapy had discouraging results.

Conclusions

Clinicians and dentists should have in mind this new complication of bisphosphonate administration to identify and treat osteonecrosis of the jaws.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0196-0709(06)00169-4

doi:10.1016/j.amjoto.2006.08.004

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 3 , Pages 158-163, May 2007